Active	Status	Sponsor type	Region	Phase	Filter
2 Active 1 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Xue, Meng
NCT05323890: Tislelizumab Combined With Neoadjuvant Radiotherapy and Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma.	Recruiting	2	15	RoW	Tislelizumab Combined With Neoadjuvant Radiotherapy and Chemotherapy, Anti-PD-1 Therapy	Shandong Cancer Hospital and Institute	Advanced Esophageal Squamous Cell Cancer	10/23	10/24
NCT06437964: Prophylactic Antibiotics in Endoscopic Secondary Prevention of Gastroesophageal Variceal Bleeding	Recruiting	N/A	224	RoW	No use of prophylactic antibiotics	Second Affiliated Hospital, School of Medicine, Zhejiang University	Cirrhosis, Liver, Hypertension, Portal, Variceal Hemorrhage	12/25	12/25